Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. METHODS: We randomly assigned 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group). The primary end point was progression-free survival. RESULTS: Progression-free survival was significantly improved with carfilzomib (median, 26.3 months, vs. 17.6 months in the control group; hazard ratio for progression or death, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P=0.0001). The median overall survival was not reached in either group at the interim analysis. The Kaplan-Meier 24-month overall survival rates were 73.3% and 65.0% in the carfilzomib and control groups, respectively (hazard ratio for death, 0.79; 95% CI, 0.63 to 0.99; P=0.04). The rates of overall response (partial response or better) were 87.1% and 66.7% in the carfilzomib and control groups, respectively (P<0.001; 31.8% and 9.3% of patients in the respective groups had a complete response or better; 14.1% and 4.3% had a stringent complete response). Adverse events of grade 3 or higher were reported in 83.7% and 80.7% of patients in the carfilzomib and control groups, respectively; 15.3% and 17.7% of patients discontinued treatment owing to adverse events. Patients in the carfilzomib group reported superior health-related quality of life. CONCLUSIONS: In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The KRd regimen has been shown to be effective in a randomized trial, and is a major option for the treatment of relapsed disease (Table 8).67”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [67]
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [27]
In the citing paper
“Pomalidomide is most often used in combination with dexamethasone, either alone or as part of triplet regimens with a variety of other anti-myeloma agents, including bortezomib45, daratumumab46 or elotuzumab47.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [46]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 2×
“The standard-risk group consisted of patients without t(4;14) or t(14;16) and with deletion 17p in less than 60% of plasma cells.”
BackgroundDiscrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citationLenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Self-citationLenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Cited by
Items 501–600 of 1,000
Baertsch, M., Schlenzka, J., Hielscher, T., Raab, M. S., Sauer, S., Merz, M., Mai, E. K., Müller‐Tidow, C., Luntz, S. P., Jauch, A. S., et al. (2025) · Blood · doi:10.1182/blood.2024027342 · Cited by 21
Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma
Jain, T., Narayanasamy, H., Mikhael, J. R., Reeder, C. B., Bergsagel, P. L., Mayo, A., Stewart, A. K., Mookadam, F., & Fonseca, R. (2017) · Blood Cancer Journal · doi:10.1038/s41408-017-0026-7 · Cited by 21
Self-citationCosta, L. J., Landau, H. J., Chhabra, S., Hari, P., Innis-Shelton, R. D., Godby, K. N., Hamadani, M., Tamari, R., Anderton, K., Dixon, P. M., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.01.036 · Cited by 21
Katodritou, E., Kyrtsonis, M., Delimpasi, S., Kyriakou, D. S., Symeonidis, A. S., Spanoudakis, E., Vasilopoulos, G., Anagnostopoulos, Α., Kioumi, A., Zikos, P., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3361-2 · Cited by 23
Willenbacher, W., Seeber, A., Steiner, N., Willenbacher, E., Gatalica, Z., Swensen, J. J., Kimbrough, J., & Vranić, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072087 · Cited by 25
“The phase III ASPIRE trial confirmed this data in providing evidence for effectiveness of carfilzomib-containing regimens against relapsed MM, including patients treated prior with bortezomib [42].”
BackgroundBortezomib-Induced Pulmonary Toxicity: A Case Report and Review of Literature
Kharel, P., Uprety, D., Chandra, A. B., Hu, Y., Belur, A. A., & Dhakal, A. (2018) · Case Reports in Medicine · doi:10.1155/2018/2913124 · Cited by 21
“respective controls (29 versus 13 percent) and cough (25 versus 14 percent), but there were no BLI-like noninfectious progressive lung injuries reported [23, 24].”
BackgroundPotent anti‐myeloma activity of the TOPK inhibitor OTS514 in pre‐clinical models
Stefka, A. T., Johnson, D. C., Rosebeck, S., Park, J., Nakamura, Y., & Jakubowiak, A. J. (2019) · Cancer Medicine · doi:10.1002/cam4.2695 · Cited by 22
Self-citationRisk and Response-Adapted Treatment in Multiple Myeloma
Cazaubiel, T., Mulas, O., Montes, L., Schavgoulidze, A., Avet‐Loiseau, H., Corre, J., & Perrot, A. (2020) · Cancers · doi:10.3390/cancers12123497 · Cited by 21
“The role of the second generation proteasome inhibitor carfilzomib (K) has been investigated after interesting results were obtained in relapsed high-risk patients [36].”
BackgroundFranken, B., van de Donk, N. W. C. J., Cloos, J. J., Zweegman, S., & Lokhorst, H. M. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716667275 · Cited by 22
“All patients received prophylaxis for thrombosis [Stewart et al. 2015].”
BackgroundGentile, M., Magarotto, V., Offidani, M., Musto, P., Bringhen, S., Petrucci, M. T., Gay, F., Larocca, A., Uccello, G., Petrungaro, A., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24621 · Cited by 21
Self-citationCost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma
Ailawadhi, S., DerSarkissian, M., Duh, M. S., Lafeuille, M.-H., Posner, G., Ralston, S., Zagadailov, E. A., Ba-Mancini, A., & Rifkin, R. M. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.01.009 · Cited by 21
New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib
Richardson, P. G. G., Kumar, S. K., Laubach, J. P., Paba‐Prada, C. E., Gupta, N., Berg, D. T., de Velde, H. J. V., & Moreau, P. (2017) · Journal of Blood Medicine · doi:10.2147/jbm.s102328 · Cited by 21
“Differences in study designs, methodologies, and patient populations limit cross-trial comparisons; however, the relative benefit with ixazomib–Rd versus placebo–Rd appeared consistent with HRs reported versus Rd for other proteasome inhibitor–Rd combinations.(29) Overall response rates and ≥VGPR rates were 78.”
Self-citationIannaccone, A., Bruno, G., Ravera, A., Gay, F., Salvini, M., Bringhen, S., Sabia, L., Avenatti, E., Veglio, F., & Milan, A. (2018) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-018-0256-1 · Cited by 21
Kalff, A., Khong, T. T., Mithraprabhu, S., Bergin, K., Reynolds, J., Bowen, K. M., Thakurta, A., Guzman, R. Z., Wang, M., Couto, S. S., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1571201 · Cited by 21
Self-citationRichardson, P. G. G., Harrison, S. J., Bringhen, S., Schjesvold, F. H., Yong, K., Campana, F., Le-Guennec, S., Macé, S., & Dimopoulos, M. A. (2021) · Future Oncology · doi:10.2217/fon-2021-0568 · Cited by 21
“Furthermore, due to restrictive trial entry criteria in most clinical trials, refractory patients may be excluded, resulting in enrolled candidates that may not be representative of the typical patient with MM [58,59].”
BackgroundSelf-citationDimopoulos, M. A., Schjesvold, F. H., Doronin, V., Vinogradova, O., Quach, H., Leleu, X. P., Montes, Y. G., Ramasamy, K., Pompa, A., Levin, M., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-021-00593-2 · Cited by 20
Self-citationCarfilzomib-induced cardiotoxicity: An analysis of the FDA Adverse Event Reporting System (FAERS)
Buck, B., Kellett, E., Addison, D., & Vallakati, A. (2022) · Journal of the Saudi Heart Association · doi:10.37616/2212-5043.1311 · Cited by 20
Watanabe, T., Tobinai, K., Matsumoto, M., Suzuki, K., Sunami, K., Ishida, T., Ando, K., Chou, T., Ozaki, S., Taniwaki, M., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13900 · Cited by 20
“…al, 2013; Wang et al, 2013; Bringhen et al, 2014; Sonneveld et al, 2015; Stewart et al, 2015), it may be necessary to optimize the use of carfilzomib, although carfilzomib and lenalidomide combined with dexamethasone has an extremely compelling efficacy and is well tolerated (Stewart et al, 2015).”
BackgroundFranssen, L. E., Raymakers, R. A. P., Buijs, A., Schmitz, M. F., van Dorp, S., Mutis, T., Lokhorst, H. M., & van de Donk, N. W. C. J. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12758 · Cited by 20
Jakubowiak, A. J., DeCara, J. M., & Mezzi, K. (2017) · Hematology · doi:10.1080/10245332.2017.1328165 · Cited by 21
“Carfilzomib is an effective anti-MM agent with demonstrated efficacy and an overall tolerable safety profile in relapsed or refractory MM [23,30].”
BackgroundSelf-citationThe Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era
Salgado, L. R., Wang, S., Adler, A., Chang, S., Ru, M., Moshier, E. L., Dharmarajan, K. V., Cho, H. J., & Bakst, R. L. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.09.009 · Cited by 21
Sidiqi, M. H., Aljama, M. A., Riaz, I. B., Dispenzieri, A. A., Muchtar, E., Buadi, F. K., Warsame, R. M., Lacy, M. Q., Dingli, D., Leung, N., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0147-7 · Cited by 21
Self-citationHow I treat elderly patients with plasma cell dyscrasias
Gavriatopoulou, M., Fotiou, D., Ntanasis‐Stathopoulos, I., Kastritis, E., Terpos, E., & Dimopoulos, M. A. (2018) · Aging · doi:10.18632/aging.101707 · Cited by 20
Self-citationCook, G., Royle, K., O’Connor, S. J. M., Cairns, D. A., Ashcroft, A. J., Williams, C. D., Hockaday, A., Cavenagh, J. D., Snowden, J. A., Ademokun, D., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15782 · Cited by 21
The pharmacologic management of multiple myeloma in older adults
Dempsey, J. L., Johns, A. C., Rosko, A. E., & Lazarus, H. M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1577822 · Cited by 20
Schroeder, M. A., Fiala, M. A., Huselton, E. J., Cardone, M. H., Jaeger, S. A., Jean, S. R., Shea, K., Ghobadi, A., Wildes, T. M., Stockerl-Goldstein, K. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1909 · Cited by 20
Bal, S., Landau, H. J., Shah, G. L., Scordo, M., Dahi, P. B., Lahoud, O. B., Hassoun, H., Hultcrantz, M. L., Korde, N., Lendvai, N. K., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.04.011 · Cited by 23
Kadowaki, H., Akazawa, H., Ishida, J., & Komuro, I. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0467 · Cited by 21
Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma
Mynott, R. L., & Wallington-Beddoe, C. T. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00074 · Cited by 22
Touzeau, C., Quignot, N., Meng, J., Jiang, H., Khachatryan, A., Singh, M., Taieb, V., Chauny, J.-V., & Désaméricq, G. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04522-y · Cited by 21
Schey, S., Brown, S., Tillotson, A., Yong, K., Williams, C. D., Davies, F. E., Morgan, G. J., Cavenagh, J. D., Cook, G., Cook, M. A., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13435 · Cited by 22
Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance
Dolloff, N. G. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.03.002 · Cited by 20
Sanchez, E., Li, M., Wang, C. S., Tang, G., Gillespie, A., Chen, H., & Berenson, J. R. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.03.002 · Cited by 19
Ludwig, H., Pönisch, W., Knop, S. T., Egle, A., Hinke, A., Schreder, M., Lechner, D., Hájek, R., Gunsilius, E., Petzer, A. L., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1666381 · Cited by 19
“In other recent myeloma trials (ASPIRE [22], ENDEAVOR [12]), a difference of 5 points has been used as cutoff, while in the FIRST study [23], differences from 5 to 12 points have been used for individual domains.”
MethodSelf-citationMinimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice
Gozzetti, A., Raspadori, D., Bacchiarri, F., Sicuranza, A., Pacelli, P., Ferrigno, I., Tocci, D., & Bocchia, M. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030120 · Cited by 21
Proteases Regulate Cancer Stem Cell Properties and Remodel Their Microenvironment
Habič, A., Novak, M., Majc, B., Turnšek, T. L., & Breznik, B. (2021) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554211035192 · Cited by 20
Szita, V. R., Mikala, G., Kozma, A., Fábián, J., Hardi, A., Alizadeh, H., Rajnics, P., Rejtő, L., Szendrei, T., Váróczy, L., et al. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610276 · Cited by 20
“9% of patients, depending on drug combinations and patient characteristics (48-50).”
BackgroundSelf-citationSellin, M., Berg, S. A., Hagen, P. A., & Zhang, J. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101448 · Cited by 21
“For example, in the APSIRE trial [9], KRd in 1st relapse showed an impressive median PFS of 26.”
BackgroundMethodCurrent use of CAR T cells to treat multiple myeloma
Firestone, R., & Mailankody, S. (2023) · Hematology · doi:10.1182/hematology.2023000434 · Cited by 20
Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma
Maybury, B. D., Cook, G., Pratt, G., Yong, K., & Ramasamy, K. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.06.004 · Cited by 22
Malard, F., Harousseau, J., & Mohty, M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.11.005 · Cited by 20
The effect of novel therapies in high-molecular-risk multiple myeloma.
Lancman, G., Tremblay, D. A., Barley, K. M., Barlogie, B., Cho, H. J., Jagannath, S., Madduri, D., Moshier, E. L., Parekh, S. S., & Chari, A. (2017) · PubMed · Cited by 19
Kiesewetter, B., Cherny, N. I., Boissel, N., Cerisoli, F., Dafni, U. G., de Vries, E. G. E., Ghia, P., Gökbuget, N., González‐Calle, V., Huntly, B. J. P., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000611 · Cited by 24
Self-citationDimopoulos, M. A., Niesvizky, R., Weisel, K. C., Siegel, D. S. D., Hájek, R., Mateos, M., Cavo, M., Huang, M., Zahlten‐Kumeli, A., & Moreau, P. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0300-y · Cited by 19
Self-citationWitte, H. M., Bonorden, B., Riecke, A., Biersack, H., Steinestel, K., Merz, H., Feller, A. C., Bernard, V., Fetscher, S., von Bubnoff, N. C. C., et al. (2020) · Cancers · doi:10.3390/cancers12040921 · Cited by 19
Grant, S. J., Mian, H. S., Giri, S., Boutin, M., Dottorini, L., Neuendorff, N. R., Krok‐Schoen, J. L., Nikita, N., Rosko, A. E., Wildes, T. M., et al. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.12.001 · Cited by 19
Latif, A., Kapoor, V., Lateef, N., Ahsan, M. J., Usman, R. M., Malik, S. U., Ahmad, N., Rosko, N., Rudoni, J., William, P., et al. (2021) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x21666210412113017 · Cited by 19
Yong, K., Hinsley, S., Auner, H. W., Bygrave, C., Kaiser, M., Ramasamy, K., Tute, R. M. D., Sherratt, D., Flanagan, L. M., Garg, M. K., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.278399 · Cited by 20
Efficace, F., Cottone, F., Sparano, F., Caocci, G., Vignetti, M., & Chakraborty, R. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.01.009 · Cited by 19
Ludwig, H., Delforge, M., Facon, T. T. F., Einsele, H., Gay, F., Moreau, P., Avet‐Loiseau, H., Boccadoro, M., Hájek, R., Mohty, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.353 · Cited by 19
Self-citationLenalidomide in multiple myeloma
Kim, Y., & Schmidt‐Wolf, I. G. H. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1033407 · Cited by 20
A Benefit–Risk Analysis Approach to Capture Regulatory Decision‐Making: Multiple Myeloma
Raju, G. K. P., Gurumurthi, K., Domike, R., Kazandjian, D. G., Landgren, O., Blumenthal, G. M., Farrell, A. T., Pazdur, R., & Woodcock, J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.871 · Cited by 19
Cella, D. F., McKendrick, J., Kudlac, A., Palumbo, A. P., Oukessou, A., Vij, R., Zyczynski, T. M., & Davis, C. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3469-4 · Cited by 19
Self-citationMcGregor, P., Boosalis, V. A., & Aragam, J. R. (2021) · SAGE Open Medical Case Reports · doi:10.1177/2050313x21994031 · Cited by 20
Boyiadzis, M. M., Bishop, M., Abonour, R., Anderson, K. C., Ansell, S. M., Avigan, D., Barbarotta, L., Barrett, A. J., van Besien, K., Bergsagel, P. L., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0188-z · Cited by 19
Self-citationBaertsch, M., Fougereau, M., Hielscher, T., Sauer, S., Breitkreutz, I., Jordan, K., Müller‐Tidow, C., Goldschmidt, H., Raab, M., Hillengaß, J., et al. (2021) · Cancers · doi:10.3390/cancers13184706 · Cited by 18
“With the most effective continuous triplet regimens, median PFS is now between 26 (KRd; ASPIRE trial) [24] and 45 months (Daratumumab/LEN/DEX [DRd]; POLLUX trial) [25] and PFS at 2 years is between ~55% and ~75%, respectively, in less heavily pretreated RRMM patients (median 1–2 prior lines of therapy).”
MethodResultInfluentialPerrot, A., Delimpasi, S., Spanoudakis, E., Frølund, U. C., Belotti, A., Oriol, A., Moreau, P., McFadden, I., Xia, Q., Arora, M., et al. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2322030 · Cited by 20
“Based on the results of previous studies evaluating KPd or KRd for the treatment of RRMM [6,14,18,19,21,22], the ORR was hypothesized to be >60%.”
BackgroundMethodResultInfluentialSelf-citationTherapeutic Landscape of Carfilzomib and Other Modulators of the Ubiquitin-Proteasome Pathway
Mitsiades, C. S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.5748 · Cited by 19
Lu, J., Lee, J. H., Huang, S., Qiu, L., Lee, J., Liu, T., Yoon, S., Kım, K., Shen, Z. X., Eom, H., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14465 · Cited by 18
Cancer and Heart Failure: Understanding the Intersection
HAMO, C. E., & Bloom, M. W. (2017) · Cardiac failure review · doi:10.15420/cfr.2016:24:2 · Cited by 18
Lendvai, N. K., Tsakos, I., Devlin, S. M., Schaffer, W. L., Hassoun, H., Lesokhin, A. M., Landau, H. J., Korde, N., Mailankody, S., Smith, E. L., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1403020 · Cited by 18
“Of note, in the ASPIRE trial, there was no increased risk of CV related deaths among patients treated on the carfilzomib arm versus the control arm [5], while the proportion of nonfatal Grade 3 or higher CV events was 3.”
BackgroundMateos, M., Goldschmidt, H., Miguel, J. F. S., Mikhael, J. R., DeCosta, L., Zhou, L., Obreja, M., Blædel, J., Szabó, Z. R., & Leleu, X. P. (2018) · Hematological Oncology · doi:10.1002/hon.2499 · Cited by 18
Self-citationEfficace, F., Boccadoro, M., Palumbo, A., Petrucci, M. T., Cottone, F., Cannella, L., Zamagni, E., Niscola, P., Kyriakou, C. A., Caravita, T., et al. (2018) · Health and Quality of Life Outcomes · doi:10.1186/s12955-018-0953-4 · Cited by 18
“Based on previous studies and on clinical grounds [44], we also assumed a minimum event rate of 35% during the study and considered a follow-up of 30 months from date of enrolment.”
MethodSelf-citationArcuri, L. J., & Américo, A. D. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04404-3 · Cited by 19
Blommestein, H. M., Franken, M. G., van Beurden-Tan, C. H. Y., Blijlevens, N. M. A., Huijgens, P. C., Sonneveld, P., Groot, C. A. U., & Zweegman, S. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.3497 · Cited by 18
Integrated Medicine for Chemotherapy-Induced Peripheral Neuropathy
Tsai, C. H., Lin, Y.-H., Li, Y.-S., Ho, T., Thuong, L. H. H., & Liu, Y.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179257 · Cited by 19
Bozic, B., Rutner, J., Zheng, C., Ruckser, R., Selimi, F., Racz, K., Köcher, M., Tatzreiter, G., & Sebesta, C. (2021) · Cancers · doi:10.3390/cancers13205036 · Cited by 20
“In frail patients or patients whose treatment objectives coincide with those of low-toxicity regimens, doublet or triplet regimens with a reduced dose can be considered [74,75].”
BackgroundTransplant Onconephrology in Patients With Kidney Transplants
Murakami, N., Webber, A. B., & Nair, V. V. (2022) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.09.002 · Cited by 19
Progress in Anticancer Drug Development Targeting Ubiquitination-Related Factors
Li, Q., & Zhang, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315104 · Cited by 19
Shibata, T., Nohara, S., Morikawa, N., Shibao, K., Shinichiro, I. T. O., Shibata, R., Toh, U., Nagafuji, K., Fukami, K., & Fukumoto, Y. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad210 · Cited by 18
Gonsalves, W. I., Rajkumar, S. V., Gertz, M. A., Dispenzieri, A. A., Lacy, M. Q., Buadi, F. K., Dingli, D., Go, R. S., Leung, N., Kapoor, P., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.91 · Cited by 18
Self-citationPharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma
Salvini, M., Troia, R., Giudice, D., Pautasso, C., Boccadoro, M., & Larocca, A. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1417388 · Cited by 18
Nielsen, L. K., Abildgaard, N., Jarden, M., & Klausen, T. (2019) · British Journal of Haematology · doi:10.1111/bjh.15759 · Cited by 20
Bruzzese, A., Derudas, D., Galli, M., Martino, E. A., Rocco, S., Conticello, C., Califano, C., Giuliani, N., Mangiacavalli, S., Farina, G., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3031 · Cited by 17
Liu, Z., Wang, H., Yang, C., Zhao, X., Hui, L., Song, J., Ding, K., & Fu, R. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011717 · Cited by 18
“These results indicated that NLRP3/ Open access caspase-1/GSDMD- N-mediated pyroptosis was successfully activated.”
Primary plasma cell leukemia 2.0: advances in biology and clinical management
Neri, A., Todoerti, K., Lionetti, M., Simeon, V., Barbieri, M., Nozza, F., Vona, G., Pompa, A., Baldini, L., & Musto, P. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1244002 · Cited by 17
“that showed to be highly effective in MM [69], are explored in newly diagnosed PPCL as induction, consolidation, and maintenance treatments, integrated within tan-”
BackgroundOutcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib
Berenson, A. M., Vardanyan, S., David, M., Wang, J., Harutyunyan, N. M., Gottlieb, J., Halleluyan, R., Spektor, T. M., Udd, K. A., Eshaghian, S., et al. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2889-2 · Cited by 18
Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement
Español, I., Romera, M., Gutiérrez‐Meca, M. D., García, M. D. C., Tejedor, A., Martínez, A., Ibáñez, J., de Arriba, F., Minguela, A., Iturbe, T., et al. (2017) · Clinical Case Reports · doi:10.1002/ccr3.1015 · Cited by 17
“Carfilzomib is a second-generation proteasome inhibitor that has demonstrated efficacy, safety, and tolerability in patients with relapsed and/or refractory multiple myeloma [7].”
BackgroundCurrent systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome
Janiga, J., Kentley, J., Nabhan, C., & Abdulla, F. R. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1347650 · Cited by 18
“Carflizomib [104] Selective proteasome inhibitor inducing accumulation of poly-ubiquinated cellular proteins leading to cell cycle arrest and apoptosis N/A N/A Phase I”
BackgroundMultiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017
Terpos, E. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.02.015 · Cited by 17
Bonello, F., Boccadoro, M., & Larocca, A. (2020) · Cancers · doi:10.3390/cancers12113106 · Cited by 18
Leleu, X. P., Beksaç, M., Chou, T., Dimopoulos, M. A., Yoon, S., Prince, H. M., Pour, L., Shelekhova, T. V., Chari, A., Khurana, M., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1832672 · Cited by 17
Self-citationIkaros Proteins in Tumor: Current Perspectives and New Developments
Xia, R., Cheng, Y., Han, X., Wei, Y., & Wei, X. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.788440 · Cited by 19
“Besides, in patients with RRMM, carfilzomib in conjunction with Len and Dex (KRd) generated markedly improved mPFS (26.3 months, vs. 17.6 months in the Len and Dex group; HR, 0.69; 95% CI, 0.57–0.83; p 0.0001) at the interim analysis and presented an improving risk-benefit profile (NCT01080391) (Stewart et al., 2015).”
BackgroundInfluentialFotiou, D., Dimopoulos, M. A., & Kastritis, E. (2022) · Cancers · doi:10.3390/cancers14246216 · Cited by 19
“In the newly diagnosed setting, VTE rates reported for carfilzomib-IMiD-based combinations range from 5 to 14%, but a uniform approach to thromboprophylaxis is missing [63,67,68].”
BackgroundSelf-citationLópez, A., Mateos, M., Oriol, A., Valero, M., Martínez‐López, J., Lorenzo, J. I. L., Pérez, M., Martínez, R., de Paz, R., Granell, M., et al. (2015) · Leukemia Research Reports · doi:10.1016/j.lrr.2015.09.002 · Cited by 19
Self-citationNew pharmacotherapy options for multiple myeloma
Mina, R., Cerrato, C., Bernardini, A., Aghemo, E., & Palumbo, A. P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1115016 · Cited by 18
“27 mg/m(2)) to Rd (KRd; Table 2).[40] A total of 792 RR patients were randomized to receive either KRd or Rd.”
MethodSelf-citationWillenbacher, E., Weger, R., Rochau, U., Siebert, U., Willenbacher, W., & Austrian Myeloma Registry (AMR) (2016) · PLoS ONE · doi:10.1371/journal.pone.0147381 · Cited by 18
Rocca, F. L., Airoldi, I., Carlo, E. D., Marotta, P., Falco, G., Simeon, V., Laurenzana, I., Trino, S., Luca, L. D., Todoerti, K., et al. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0338-4 · Cited by 17
Alhuraiji, A., Naqvi, K. Z., Huh, Y. O., Ho, C., Verstovšek, S., & Bose, P. (2017) · Clinical Case Reports · doi:10.1002/ccr3.1264 · Cited by 17
Gössi, U., Jeker, B., Taleghani, B. M., Bacher, U., Novak, U., Betticher, D. C., Egger, T., Zander, T., & Pabst, T. (2018) · Hematological Oncology · doi:10.1002/hon.2490 · Cited by 17
“of randomized studies investigating prolonged administration of triple combinations involving novel compounds as described above.(38-44) We found that the time to progression (TTP) after the first ASCT was the most important factor predicting both PFS and OS after diagnosis of relapse, which is consistent with previou…”
BackgroundResultImmunomodulatory Agents for Multiple Myeloma
Minařík, J., & Ševčíková, S. (2022) · Cancers · doi:10.3390/cancers14235759 · Cited by 17
Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma
Parekh, D. S., Tiger, Y. K., Jamouss, K. T., Hassani, J., Zerdan, M. B., & Raza, S. (2024) · Cancers · doi:10.3390/cancers16172931 · Cited by 18
“…of RRMM [32,33]; however, subsequent research typically utilizes lenalidomide–dexamethasone as a control group to assess outcomes with the addition of a third agent such as daratumumab [34], the proteasome inhibitors carfilzomib [1] or ixazomib [2], or the anti-SLAMF7 antibody elotuzumab [15].”
Dimopoulos, M. A., Sonneveld, P., Siegel, D. S. D., Palumbo, A. P., & Miguel, J. F. S. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv325 · Cited by 16
Self-citationZou, Y., Ma, X., Yu, H., Hu, C., Fan, L., & Ran, X. (2016) · Oncotarget · doi:10.18632/oncotarget.10768 · Cited by 17
Carfilzomib boosted combination therapy for relapsed multiple myeloma
Steiner, R. E., & Manasanch, E. E. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s102756 · Cited by 16
“In the ASPIRE trial, 70% of the patients in the KRd group and 78% of the patients in the Rd group discontinued treat-ment, most commonly owing to disease progression (39.8% and 50.1%, respectively) or AEs.”
InfluentialBrown, J., Plummer, R., Bauer, T. M., Anthony, S. P., Sarantopoulos, J., Vos, F. D., White, M., Schupp, M., Ou, Y. C., & Vaishampayan, U. N. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0086-1 · Cited by 16
“Within the two phase 3 studies, PX-171-0009 (ASPIRE) and 2011-003 (ENDEAVOR), the eligibility criteria allowed for the enrollment of multiple myeloma patients with baseline mild hepatic impairment (alanine aminotransferase [ALT]/aspartate aminotransferase (AST) >upper limit of normal (ULN) or total bilirubin >ULN) wit…”
BackgroundDCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma
Goldsmith, S. R., Fiala, M. A., Wang, B., Schroeder, M. A., Wildes, T. M., Ghobadi, A., Stockerl-Goldstein, K. E., & Vij, R. (2020) · Annals of Hematology · doi:10.1007/s00277-020-03970-2 · Cited by 16
Palmieri, S., Rocco, S., Vitagliano, O., Catalano, L., Cerchione, C., Vincelli, I. D., Scopelliti, A., Gentile, M., Farina, G., Barone, M., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04158-4 · Cited by 16
Role of the Ubiquitin Proteasome System in the Regulation of Blood Pressure: A Review
Yamazaki, O., Hirohama, D., Ishizawa, K., & Shibata, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155358 · Cited by 17
“It exhibited a higher efficacy in the treatment of patients with relapsed and/or refractory multiple myeloma when applied in combination with dexamethasone with or without lenalidomide [69,70].”
BackgroundVenner, C. P., LeBlanc, R., Sandhu, I., White, D. J., Belch, A. R., Reece, D. E., Chen, C. I., Dolan, S., Lalancette, M., Louzada, M., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26147 · Cited by 16
Metadata
- Authors
- Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A. J., San-Miguel, J. F., Ludwig, H., Wang, M., Maisnar, V., Minarik, J., Bensinger, W. I., Mateos, M.-V., Ben-Yehuda, D., Kukreti, V., Zojwalla, N., Tonda, M. E., Yang, X., Xing, B., Moreau, P., & Palumbo, A.
- Affiliations
- Mayo Clinic in Arizona (US)
- Mayo Clinic (US)
- Alexandra Hospital (GR)
- Semmelweis University (HU)
- Josep Carreras Leukaemia Research Institute (ES)
- University of Ostrava (CZ)
- Hospital Clínic de Barcelona (ES)
- Hackensack University Medical Center (US)
- Queen Giovanna Hospital (BG)
- University Multipurpose Hospital for Active Treatment "Sveti Georgi" (BG)
- Somogy Megyei Kaposi Mór Oktató Kórház (HU)
- The First Republican Clinical Hospital of the Ministry of Health of the Udmurt Republic (RU)
- University of Chicago (US)
- Wilhelminen Hospital (AT)
- The University of Texas MD Anderson Cancer Center (US)
- Charles University (CZ)
- Fred Hutch Cancer Center (US)
- Princess Margaret Cancer Centre (CA)
- Université de Nantes (FR)
- University of Turin (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-01-08
- Volume
- 372
- Issue
- 2
- Pages
- 142-152
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1985864219
- Semantic Scholar
- 6c229c6500f2d44efe03b42aea66351261666d13
- Cited by
- 1,332
- References
- 33
- Citations by year
- 2026: 36 · 2025: 62 · 2024: 63 · 2023: 79 · 2022: 112 · 2021: 137 · 2020: 149 · 2019: 131 · 2018: 166 · 2017: 168 · 2016: 148 · 2015: 77
- FWCI
- 93.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- carfilzomib, lenalidomide, dexamethasone, relapsed multiple myeloma, proteasome inhibitors, progression-free survival, overall survival, adverse events, health-related quality of life, combination therapy, treatment response, interim analysis, treatment discontinuation, stringent complete response, partial response, complete response, overall response rate
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Oligopeptides, Recurrence, Thalidomide, Kaplan-Meier Estimate, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.